GT Metabolic Solutions Secures Series C Growth Investment
The company plans to use the new funding to support its global commercial launch and surgical expansion.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you believe new medical technologies effectively lower the risks of serious surgical complications?
GT Metabolic Solutions has closed a Series C growth investment led by J.P. Morgan Life Sciences Private Capital. This partnership marks the first institutional financing for the medical device firm.
Why it matters
The capital will fuel the company’s worldwide commercial launch and expansion into new colorectal and endoscopic surgery settings. It also aims to accelerate surgeon training and broader product development.
J.P. Morgan Life Sciences Private Capital has now completed five total transactions, with this latest round supporting GT Metabolic’s FDA-cleared magnetic technology. The firm's device aims to improve outcomes where 18% of procedures face complications.
The players
GT Metabolic Solutions
A medical device company headquartered in Minneapolis that holds FDA De Novo and 510(k) clearances for its magnetic anastomosis technology.
J.P. Morgan Life Sciences Private Capital
An investment firm that focuses on life sciences and recently completed its fifth transaction through this growth financing.
The details
The company’s technology utilizes linear magnetic compression to perform incisionless, sutureless, and staple-free gastrointestinal anastomoses. It is designed for deployment through endoscopic, robotic, or laparoscopic surgical access.
Timeline
October 28, 2026: GT Metabolic Solutions announced the closing of its Series C investment.
Market Landscape
This investment represents a significant shift for the company, moving from early regulatory milestones like the FDA 510(k) clearance process to a full-scale commercial phase. By securing institutional backing, the firm positions itself to compete more aggressively in the surgical device market.
While this investment is a corporate milestone, the broader impact for patients lies in the potential for safer, incisionless surgical options that avoid traditional sutures. Patients undergoing gastrointestinal procedures may eventually see increased availability of these magnetic technologies in their local surgical centers.
The takeaway
Advancements in magnetic surgery technology aim to reduce the significant complication rates associated with traditional gastrointestinal procedures. Surgeons and health systems are increasingly evaluating these sutureless methods to improve recovery times and patient safety.
Further reading
For more information on the evolving medical landscape, visit the Healthcare section.
More information
Find more details on the company’s technology via the GT Metabolic company information portal.
Source note: This article includes information reported by Financial Post.
Live Poll
Do you believe new medical technologies effectively lower the risks of serious surgical complications?
